Cogent Biosciences' Bezuclastinib Shows Significant Symptomatic Improvement in NonAdvSM Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Should l Buy COGT?
Source: Globenewswire
- Clinical Trial Results: In the SUMMIT trial, Bezuclastinib demonstrated a significant average improvement of 24.3% in symptom severity score (TSS) among 118 patients with NonAdvSM over 24 weeks, outperforming the placebo group's 15.4%, indicating its therapeutic potential.
- Long-term Efficacy: New 48-week data reveal that Bezuclastinib's efficacy continues to deepen, with an average TSS improvement of 32.0% and 56.4% of patients achieving a ≥50% reduction in TSS, underscoring its effectiveness for chronic use.
- Safety Profile: Bezuclastinib exhibits a favorable safety and tolerability profile, with 98.3% of treatment-emergent adverse events being low-grade, and only 4.2% of patients experiencing serious adverse events, highlighting its safety for long-term administration.
- Future Outlook: Cogent plans to submit a New Drug Application for Bezuclastinib to the FDA in December 2025 and will share additional data during an upcoming investor conference call, further enhancing its market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COGT
Wall Street analysts forecast COGT stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 34.000
Low
34.00
Averages
50.36
High
67.00
Current: 34.000
Low
34.00
Averages
50.36
High
67.00
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cogent Biosciences' New Drug Application Accepted by FDA
- Stock Surge: Cogent Biosciences (COGT) shares are up approximately 8% in Monday morning trading, currently priced at $36.80, reflecting a positive market reaction to the new drug application, having opened at $36.79 and peaked at $37.18.
- FDA Approval Milestone: The U.S. Food and Drug Administration (FDA) has accepted Cogent's New Drug Application for bezuclastinib, setting a Prescription Drug User Fee Act target action date of December 30, 2026, marking a significant milestone in the company's drug development journey.
- Clinical Trial Data Support: The application is based on encouraging data from the pivotal SUMMIT trial, which demonstrated clinically meaningful and highly statistically significant improvements across primary and all key secondary endpoints, bolstering market confidence in the drug's potential.
- Annual Trading Range: Over the past year, Cogent's stock has traded between $3.72 and $43.73, with the current price performance indicating investor optimism regarding the company's future growth prospects.
See More
Sphera Increases Stake in Cogent Biosciences
- Share Acquisition: Sphera Funds Management disclosed an acquisition of 279,974 shares of Cogent Biosciences in an SEC filing dated February 17, 2026, with an estimated transaction value of approximately $7.87 million, indicating strong confidence in the company's prospects.
- Value Increase: Following this acquisition, Cogent now represents about 2.6% of Sphera's U.S. equity portfolio, with the position's value rising by $12.03 million at quarter-end, reflecting optimistic market expectations for its future developments.
- Outstanding Stock Performance: As of February 17, 2026, Cogent's stock price stood at $37.62, marking a staggering 365% increase over the past year, significantly outperforming the S&P 500's roughly 20% gain, showcasing its robust performance in the biotech sector.
- Significant Clinical Progress: Cogent's lead product candidate, CGT9486, targets specific genetic mutations for precision therapy, with multiple regulatory catalysts expected in 2026; if successful, the company could rapidly transition from a clinical-stage developer to a commercial oncology firm, driving future growth.
See More
Sphera Funds Increases Stake in Cogent Biosciences
- Share Acquisition: Sphera Funds acquired 279,974 shares of Cogent Biosciences in Q4 2025, with an estimated transaction value of $7.87 million, indicating confidence in the company's growth potential.
- Increased Position Value: By quarter-end, Sphera's total stake reached 378,500 shares valued at $13.44 million, reflecting a $12.03 million increase, which underscores positive market sentiment towards Cogent.
- Significant Clinical Progress: Cogent's lead drug candidate, bezuclastinib, has shown promising clinical results, particularly in late-stage trials for gastrointestinal stromal tumors, where the treatment group achieved a median progression-free survival of 16.5 months, significantly better than the 9.2 months of the current standard treatment.
- Strong Financial Position: Cogent finished 2025 with approximately $900 million in cash and marketable securities, sufficient to fund operations into 2028, positioning the company for a potential swift transition from a clinical-stage developer to a commercial oncology entity if regulatory decisions favor them.
See More
Bezuclastinib Shows Significant Clinical Trial Results
- Significant Efficacy Improvement: Bezuclastinib treatment resulted in a mean TSS reduction of 32.0 points at 48 weeks, reflecting a 56% relative improvement from baseline, indicating its potential efficacy in Non-Advanced Systemic Mastocytosis patients.
- Widespread Symptom Improvement: 99% of patients achieved over a 50% reduction in serum tryptase levels at 48 weeks, with 83% normalizing, highlighting Bezuclastinib's significant impact on enhancing patient quality of life.
- Bone Density Enhancement: Patients treated with Bezuclastinib exhibited clinically meaningful improvements in bone mineral density at 24 weeks, further supporting its potential as a disease-modifying agent, particularly in high unmet need populations.
- Favorable Safety Profile: Bezuclastinib demonstrated a good safety and tolerability profile, supporting its potential for chronic use in Non-Advanced Systemic Mastocytosis patients, positioning it as a likely preferred standard of care.
See More
COGENT SECURITY SECURES FUNDING LED BY BAIN CAPITAL VENTURES, WITH CONTRIBUTIONS FROM GREYLOCK PARTNERS AND DEFINITION
Funding Announcement: COGENT SECURITY has secured funding led by Bain Capital Ventures, indicating strong investor confidence in the company's potential.
Investor Participation: The funding round also saw participation from existing investor Greylock Partners, highlighting ongoing support from established venture capital firms.
See More
Rock Springs Capital Reduces Stake in Cogent Biosciences
- Stake Reduction Details: Rock Springs Capital Management disclosed a reduction of 159,278 shares in Cogent Biosciences during Q4 2026, with an estimated transaction value of $4.48 million, indicating that despite the reduction, confidence in the company remains intact.
- Market Performance Analysis: As of February 16, 2026, Cogent's share price stood at $36.53, reflecting a remarkable 346.6% increase over the past year, significantly outperforming the S&P 500 by 334.8 percentage points, showcasing its strong position in the biotech sector.
- Financial Overview: Cogent boasts a market capitalization of $5.82 billion, and despite a net loss of $294.37 million over the past twelve months, it holds approximately $901 million in cash and marketable securities, ensuring operational funding through 2028.
- Future Growth Potential: Cogent is advancing multiple new drug applications, including bezuclastinib for non-advanced systemic mastocytosis, with an APEX NDA submission expected in the first half of 2026, demonstrating its ongoing innovation in oncology.
See More
Cogent Biosciences' New Drug Application Accepted by FDA
- Stock Surge: Cogent Biosciences (COGT) shares are up approximately 8% in Monday morning trading, currently priced at $36.80, reflecting a positive market reaction to the new drug application, having opened at $36.79 and peaked at $37.18.
- FDA Approval Milestone: The U.S. Food and Drug Administration (FDA) has accepted Cogent's New Drug Application for bezuclastinib, setting a Prescription Drug User Fee Act target action date of December 30, 2026, marking a significant milestone in the company's drug development journey.
- Clinical Trial Data Support: The application is based on encouraging data from the pivotal SUMMIT trial, which demonstrated clinically meaningful and highly statistically significant improvements across primary and all key secondary endpoints, bolstering market confidence in the drug's potential.
- Annual Trading Range: Over the past year, Cogent's stock has traded between $3.72 and $43.73, with the current price performance indicating investor optimism regarding the company's future growth prospects.
See More
Sphera Increases Stake in Cogent Biosciences
- Share Acquisition: Sphera Funds Management disclosed an acquisition of 279,974 shares of Cogent Biosciences in an SEC filing dated February 17, 2026, with an estimated transaction value of approximately $7.87 million, indicating strong confidence in the company's prospects.
- Value Increase: Following this acquisition, Cogent now represents about 2.6% of Sphera's U.S. equity portfolio, with the position's value rising by $12.03 million at quarter-end, reflecting optimistic market expectations for its future developments.
- Outstanding Stock Performance: As of February 17, 2026, Cogent's stock price stood at $37.62, marking a staggering 365% increase over the past year, significantly outperforming the S&P 500's roughly 20% gain, showcasing its robust performance in the biotech sector.
- Significant Clinical Progress: Cogent's lead product candidate, CGT9486, targets specific genetic mutations for precision therapy, with multiple regulatory catalysts expected in 2026; if successful, the company could rapidly transition from a clinical-stage developer to a commercial oncology firm, driving future growth.
See More
Sphera Funds Increases Stake in Cogent Biosciences
- Share Acquisition: Sphera Funds acquired 279,974 shares of Cogent Biosciences in Q4 2025, with an estimated transaction value of $7.87 million, indicating confidence in the company's growth potential.
- Increased Position Value: By quarter-end, Sphera's total stake reached 378,500 shares valued at $13.44 million, reflecting a $12.03 million increase, which underscores positive market sentiment towards Cogent.
- Significant Clinical Progress: Cogent's lead drug candidate, bezuclastinib, has shown promising clinical results, particularly in late-stage trials for gastrointestinal stromal tumors, where the treatment group achieved a median progression-free survival of 16.5 months, significantly better than the 9.2 months of the current standard treatment.
- Strong Financial Position: Cogent finished 2025 with approximately $900 million in cash and marketable securities, sufficient to fund operations into 2028, positioning the company for a potential swift transition from a clinical-stage developer to a commercial oncology entity if regulatory decisions favor them.
See More
Bezuclastinib Shows Significant Clinical Trial Results
- Significant Efficacy Improvement: Bezuclastinib treatment resulted in a mean TSS reduction of 32.0 points at 48 weeks, reflecting a 56% relative improvement from baseline, indicating its potential efficacy in Non-Advanced Systemic Mastocytosis patients.
- Widespread Symptom Improvement: 99% of patients achieved over a 50% reduction in serum tryptase levels at 48 weeks, with 83% normalizing, highlighting Bezuclastinib's significant impact on enhancing patient quality of life.
- Bone Density Enhancement: Patients treated with Bezuclastinib exhibited clinically meaningful improvements in bone mineral density at 24 weeks, further supporting its potential as a disease-modifying agent, particularly in high unmet need populations.
- Favorable Safety Profile: Bezuclastinib demonstrated a good safety and tolerability profile, supporting its potential for chronic use in Non-Advanced Systemic Mastocytosis patients, positioning it as a likely preferred standard of care.
See More
COGENT SECURITY SECURES FUNDING LED BY BAIN CAPITAL VENTURES, WITH CONTRIBUTIONS FROM GREYLOCK PARTNERS AND DEFINITION
Funding Announcement: COGENT SECURITY has secured funding led by Bain Capital Ventures, indicating strong investor confidence in the company's potential.
Investor Participation: The funding round also saw participation from existing investor Greylock Partners, highlighting ongoing support from established venture capital firms.
See More
Rock Springs Capital Reduces Stake in Cogent Biosciences
- Stake Reduction Details: Rock Springs Capital Management disclosed a reduction of 159,278 shares in Cogent Biosciences during Q4 2026, with an estimated transaction value of $4.48 million, indicating that despite the reduction, confidence in the company remains intact.
- Market Performance Analysis: As of February 16, 2026, Cogent's share price stood at $36.53, reflecting a remarkable 346.6% increase over the past year, significantly outperforming the S&P 500 by 334.8 percentage points, showcasing its strong position in the biotech sector.
- Financial Overview: Cogent boasts a market capitalization of $5.82 billion, and despite a net loss of $294.37 million over the past twelve months, it holds approximately $901 million in cash and marketable securities, ensuring operational funding through 2028.
- Future Growth Potential: Cogent is advancing multiple new drug applications, including bezuclastinib for non-advanced systemic mastocytosis, with an APEX NDA submission expected in the first half of 2026, demonstrating its ongoing innovation in oncology.
See More
